SuppreMol's Clinical Data in SLE for its Lead Product SM101 Accepted for Presentation at the 2014 ACR/ARHP Annual Meeting
![](/46/pdcnewsitem/03/36/41/kJ3pNv84VosU7nA.jpg)
SuppreMol GmbH, a biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, has announced that an abstract detailing Phase IIa clinical data of SM101 in SLE patients has been accepted for presentation at the 2014 ACR/ARHP Annual Meeting, to be held in Boston, Massachusetts, USA, 14–19 November 2014.
The abstract "SM101, a Novel Recombinant, Soluble, Human FcyIIB Receptor, in the Treatment of Systemic Lupus Erythematosus: Results of a Double-Blind, Placebo-Controlled Multicenter Study" will be presented in the session "Systemic Lupus Erythematosus — Clinical Aspects and Treatment: Novel Therapies for Systemic Lupus Erythematosus" on Tuesday, 18 November at 2:30 PM EST (Presentation Number 2787).
The Phase IIa clinical trial enrolled 51 SLE patients for 6 months. Patients received 6 mg/kg or 12 mg/kg SM101 or placebo and randomized to a ratio of 2:2:1. The clinically relevant endpoints were SLEDAI, BILAG, PGA and Overall Response, equivalent to the Responder Index. SM101 showed a clear numerical dose response in all four key endpoints at 6 months. SM101 confirmed its excellent safety profile in this clinical trial.
Mike Tansey, Chief Development Officer at SuppreMol commented: "We are very excited by the promising therapeutic activity and excellent safety profile seen in this first SLE trial with SM101. Acceptance of our encouraging data for oral presentation by the ACR/ARHP Annual Meeting and the positive response we have received from our clinical advisors provide a further incentive for us to continue the expeditious development of SM101 to help patients suffering from SLE."
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance